Overview

A Study of YL202 in Patients With Advanced Solid Tumors

Status:
NOT_YET_RECRUITING
Trial end date:
2027-02-28
Target enrollment:
Participant gender:
Summary
This study is a multicenter, open-label, phase II study of YL202 in China to evaluate the efficacy, safety, and PK characteristics of YL202 in selected patients with advanced solid tumors.
Phase:
PHASE2
Details
Lead Sponsor:
MediLink Therapeutics (Suzhou) Co., Ltd.